Shots:
Jazz Pharmaceuticals has entered into a definitive agreement to acquire Actio Biosciences, incl. its asset ABS-1230 for the treatment of KCNT1+ epilepsy; closing expected by Q4’26
Under the merger, Actio shareholders will receive $820M upfront & ~$500M in approval and sales milestones. Actio will spin out a new private company, excl. ABS-1230, which remains…
